Learning Objectives:

1.  To provide an overview the TMA-spectrum conditions 
2.  Discuss the existing evidence for the current medical management of TMAs, i.e. Eculizumab and 
     Caplacizumab 
3.  Discuss the future directions and how targeted therapies distort the paradigm of TMAs treatment 

Session date: 
Thursday, December 10, 2020 - 8:00am to 9:00am
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Koosha Paydary, MD